Pharsight

Biogen Ma patents expiration

1. Qalsody patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10385341 BIOGEN MA Compositions for modulating SOD-1 expression
Apr, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10968453 BIOGEN MA Compositions for modulating SOD-1 expression
Apr, 2035

(11 years from now)

US10669546 BIOGEN MA Compositions for modulating SOD-1 expression
Apr, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 25, 2030
New Chemical Entity Exclusivity (NCE) Apr 25, 2028

Drugs and Companies using TOFERSEN ingredient

NCE-1 date: 2027-04-26

Market Authorisation Date: 25 April, 2023

Treatment: Treatment of amyotrophic lateral sclerosis (als) in adults who have a mutation in the superoxide dismutase 1 (sod1) gene

Dosage: SOLUTION;INTRATHECAL

More Information on Dosage

QALSODY family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic